Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMCISION II in advanced oral cavity squamous cell carcinoma
NL-OMON59978Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in Oral Mucosal Carcinoma and head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Clinical complete response with organ preservation at 24 months and Recurrence-free survival non-inferiority. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
Oral Mucosal Carcinomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON59978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59978.